Tirzepatide, the popular diabetes drug sold as Mounjaro and Zepbound, more than doubles the risk of developing a severe, sight-threatening eye condition in patients who already have eye damage, according to a large study published recently in Diabetologia.
The research found that 1.1 percent of tirzepatide users developed proliferative diabetic retinopathy (PDR)—a serious form of diabetic eye disease that can cause blindness—compared to just 0.5 percent of patients not taking the drug.
